risedronic acid has been researched along with docetaxel anhydrous in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Coenen, JL; Creemers, GJ; Dalesio, O; de Jong, PC; de Wit, R; Fosså, SD; Gerritsen, W; Loosveld, OJ; Meulenbeld, HJ; Polee, M; Ten Tije, AJ; van Werkhoven, ED | 1 |
| Blaisse, RJ; de Wit, R; Erjavec, Z; Gerritse, FL; Los, M; Meulenbeld, HJ; Roodhart, JM; Smilde, TJ; van der Velden, AM | 1 |
| Aiba, S; Fujimura, T; Furudate, S; Haga, T; Hashimoto, A; Kambayashi, Y | 1 |
| Aiba, S; Fujimura, T; Furudate, S; Kakizaki, A; Kambayashi, Y | 1 |
1 review(s) available for risedronic acid and docetaxel anhydrous
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for risedronic acid and docetaxel anhydrous
| Article | Year |
|---|---|
Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Castration; Disease Progression; Docetaxel; Etidronic Acid; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Netherlands; Norway; Pain; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risedronic Acid; Risk Assessment; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2012 |
3 other study(ies) available for risedronic acid and docetaxel anhydrous
| Article | Year |
|---|---|
Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Etidronic Acid; Humans; Male; Middle Aged; Multicenter Studies as Topic; Netherlands; Prednisone; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Retrospective Studies; Risedronic Acid; Survival Analysis; Taxoids | 2013 |
Comparison of immunosuppressive and cytotoxic cells in angiosarcoma: development of a possible supportive therapy for angiosarcoma.
Topics: Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Apyrase; Docetaxel; Drug Therapy, Combination; Enzyme Inhibitors; Etidronic Acid; Female; Forkhead Transcription Factors; Hemangiosarcoma; Humans; Macrophages; Male; Matrix Metalloproteinase 9; Poly(A)-Binding Proteins; Receptors, Cell Surface; Risedronic Acid; Skin Neoplasms; T-Cell Intracellular Antigen-1; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Taxoids | 2013 |
Immunomodulatory effect of bisphosphonate risedronate sodium on CD163+ arginase 1+ M2 macrophages: the development of a possible supportive therapy for angiosarcoma.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Arginase; Calcium Channel Blockers; Cytokines; Docetaxel; Etidronic Acid; Hemangiosarcoma; Humans; Immunologic Factors; Macrophages; Matrix Metalloproteinase 9; Models, Biological; Nitric Oxide Synthase Type II; Receptors, Cell Surface; Risedronic Acid; RNA, Messenger; Taxoids; Th2 Cells | 2013 |